The Role of Perirenal Fat As Predictor in Diabetic Nephropathy

1 detect the relationship between perirenal fat thickness (PrFT) and estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes (T2DM).

2)Explored the relationship between PRF thickness and the onset and progression of albuminuria in patients with diabetes 3)Evaluate associations between obesity-related markers with albuminuria and advanced kidney disease in patients with type 2 diabetes mellitus (DM)

Study Overview

• Status: Not yet recruiting
• Conditions: Diabetic
• Intervention / Treatment: Device: Sonar

Detailed Description

Diabetic kidney disease (DKD) is the most frequent and severe complication of diabetes mellitus (DM). Approximately 40% of patients with diabetes present with proteinuria and renal dysfunction and DKD reportedly account for 50% of newly diagnosed end-stage renal disease (ESRD) . Metabolic disorders caused by hyperglycemia in DKD can lead to both glucose and lipid metabolism disorders. Not only hyperglycemia, many factors including obesity have been reported to be risk factors for diabetic kidney disease .

Body mass index (BMI) and waist circumference (WC), widely used as obesity indexes, have been proved to aggravate the development of CKD in different subsets of patients , but BMI and WC lack detailed information about the distribution of body fat. Body fat is now usually divided into subcutaneous fat and visceral fat according to the anatomical and physiological functions of fat deposition . Visceral fat has been thought to be associated with the progression of CKD .

Recently, new anthropometric and imaging methods have been used to assess visceral fat in clinical practice and research. Perirenal fat is a fat pad surrounding the kidneys, located between the renal fibrous membrane and the renal fascia in the retroperitoneal space .PRF has been reported to be associated with renal disease in various ways.Additionally, it has been proved that renal sinus fat was associated with an increased risk of CKD in general subjects through inflammatory signaling

• Study Type: Observational
• Enrollment (Estimated): 100

Contacts and Locations

• Study Contact: Name: Marina Sobhy Masoud, Resident of Nephrology; Phone Number: 01223602270 093 2346730; Email: marinasobhygerges@gmail.com
• Study Contact Backup: Name: Salma Mokhtar Osama, lecturer; Phone Number: 01224309971 088 2654760; Email: Salammkhtarosman@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Follow up patient is T2DM

Description

Inclusion Criteria:

- Patients with T2DM aged 18-70 were included in this study. T2DM was diagnosed according to American Diabetes Association (ADA) ,Data collection will obtained over one year from October 2024 to October 2025.

Clinical diagnosis of Alzheimer's Disease Must be able to swallow tablets

Exclusion Criteria:

• b. Exclusion criteria:

  1. patients with a history of malignancy and surgical trauma.
  2. patients diagnosed with nondiabetic renal diseases
  3. Patients with renal replacement therapy (renal transplant or dialysis patients), renal morphological abnormalities (difference in kidney length between the two cm, solitary kidney or multiple kidneys, congenital kidney abnormalities, polycystic kidney, and hydronephrosis), liver cirrhosis.
  4. Insulin dependent diabetes
  5. Thyroid disease

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
the thickness of preirenal fat in diabetic patients	Follow up the patient with sonar to detect early changes in perirenal fat in diabetic patient. perirenal fat is the thickness of the fat capsule along the long axis of the kidney, and pararenal fat was the thickness of the fat layer measured between the medial surface of abdominal muscle tissue and the renal fascia.	Basaline

Collaborators and Investigators

• Sponsor: Assiut University

Study record dates

Study Major Dates

• Study Start (Estimated): March 1, 2025
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: May 26, 2024
• First Submitted That Met QC Criteria: February 3, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 3, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Endocrine System Diseases; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Diabetes Mellitus; Diabetes Complications; Diabetic Nephropathies
• Other Study ID Numbers: Perirenal fat in diabetic

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No